Several studies have addressed the interaction of the HIV Tat protein with the cell surface. Our analysis of the cell attachment-promoting activity of Tat and peptides derived from it revealed that the basic domain of Tat, not the arg-gly-asp (RGD) sequence, is required for cell attachment to Tat. Affinity chromatography with Tat peptides and immunoprecipitation with various anti-integrin antibodies suggest that the vitronectin-binding integrin, alpha v beta 5, is the cell surface protein that binds to the basic domain of Tat. The Tat basic domain contains the sequence RKKRRQRRR. A related sequence, KKQRFRHRNRKG, present in the heparin-binding domain of an alpha v beta 5 ligand, vitronectin, also bound alpha v beta 5 in affinity chromatography and, in combination with an RGD peptide, was an inhibitor of cell attachment to vitronectin. The alpha v beta 5 interaction with these peptides was not solely due to high content of basic amino acids in the ligand sequences; alpha v beta 5 did not bind substantially to peptides consisting entirely of arginine or lysine, whereas a beta 1 integrin did bind to these peptides. The interaction of alpha v beta 5 with Tat is atypical for integrins in that the binding to Tat is divalent cation independent, whereas the binding of the same integrin to an RGD-containing peptide or to vitronectin requires divalent cations. These data define an auxiliary integrin binding specificity for basic amino acid sequences. These basic domain binding sites may function synergistically with the binding sites that recognize RGD or equivalent sequences.
Article|
April 15 1993
A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin.
B E Vogel,
B E Vogel
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
S J Lee,
S J Lee
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
A Hildebrand,
A Hildebrand
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
W Craig,
W Craig
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
M D Pierschbacher,
M D Pierschbacher
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
F Wong-Staal,
F Wong-Staal
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
E Ruoslahti
E Ruoslahti
La Jolla Cancer Research Foundation, California 92037.
Search for other works by this author on:
B E Vogel
La Jolla Cancer Research Foundation, California 92037.
S J Lee
La Jolla Cancer Research Foundation, California 92037.
A Hildebrand
La Jolla Cancer Research Foundation, California 92037.
W Craig
La Jolla Cancer Research Foundation, California 92037.
M D Pierschbacher
La Jolla Cancer Research Foundation, California 92037.
F Wong-Staal
La Jolla Cancer Research Foundation, California 92037.
E Ruoslahti
La Jolla Cancer Research Foundation, California 92037.
Online ISSN: 1540-8140
Print ISSN: 0021-9525
J Cell Biol (1993) 121 (2): 461–468.
Citation
B E Vogel, S J Lee, A Hildebrand, W Craig, M D Pierschbacher, F Wong-Staal, E Ruoslahti; A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin.. J Cell Biol 15 April 1993; 121 (2): 461–468. doi: https://doi.org/10.1083/jcb.121.2.461
Download citation file: